Dr. Robert G. Bota, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 80
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CA license A103585 (first issued 2008; current) · AZ license 73114
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- College Medical Center Long Beach, CA
Medical groups
- Harbor Psychiatry and Mental Health Professional Corporation (19 clinicians)
- Silvan Medical Consulting Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 1,185
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 542 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 168 | 56 |
| Psychotherapy with evaluation and management visit, 30 minutes | 70 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 21 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 28 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
| Psychiatric diagnostic evaluation with medical services | 18 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Alprazolam Other prescribers in Costa Mesa, CA | 25 |
| Duloxetine Hcl Other prescribers in Costa Mesa, CA | 25 |
| Clonazepam Other prescribers in Costa Mesa, CA | 25 |
| Sertraline Hcl Other prescribers in Costa Mesa, CA | 22 |
| Bupropion Xl (bupropion hcl) Other prescribers in Costa Mesa, CA | 19 |
| Buspirone Hcl Other prescribers in Costa Mesa, CA | 15 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Costa Mesa, CA | 14 |
| Escitalopram Oxalate Other prescribers in Costa Mesa, CA | 14 |
| Dayvigo (lemborexant) | 13 |
| Lorazepam Other prescribers in Costa Mesa, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 15 payments worth $774 in total to this clinician.
| Food and Beverage | $774 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $768,036 in research payments for these studies, mostly to the institutions running them.
- An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - BXCL501401
Bioxcel Therapeutics, Inc. - A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Axsome Therapeutics, Inc. - A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia
E.r. Squibb & Sons, L.l.c. - An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Sumitomo Pharma America, Inc. · Completed · NCT05741528 - A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06951698 - A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06929273
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.